ASBPW Aspire Biopharma Holdings, Inc. - Warrant
NASDAQ · 在 SEC EDGAR 上查看 ↗ 收盘 八月 28, 2026 10-K/10-Q 八月 13, 2026ASBPW 股票快照 价格、市值、P/E、EPS、ROE、负债/权益、52周范围
ASBPW 股价图表 包含技术指标的日 OHLCV — 平移、缩放和自定义您的视图
Bar granularity adapts to the selected period — hover the chart to see open/high/low/close for a bar.
| 除息日 | Split | 类型 |
|---|---|---|
| 2026年5月11日 | 1-for-30 | Reverse |
10年表现 收入、净利润、利润率和每股收益趋势
估值 P/E、P/S、P/B、EV/EBITDA 比率 — 该股票是昂贵还是便宜?
基本面数据不足,尚无法计算此比率组。
盈利能力 毛利率、营业利润率和净利率;股本回报率 (ROE)、资产回报率 (ROA)、投入资本回报率 (ROIC)
| 指标 | 5年趋势 | ASBPW | 同行中位数 | 结论 |
|---|---|---|---|---|
| Gross Margin (毛利率) | -1.9% | · | · | |
| Operating Margin (营业利润率) | -312017.0% | · | · | |
| Net Profit Margin (净利润率) | -394725.1% | · | · | |
| ROA | -3353.2% | · | · | |
| ROE | 306.1% | · | · |
财务健康 债务、流动性、偿付能力 — 资产负债表强度
| 指标 | 5年趋势 | ASBPW | 同行中位数 | 结论 |
|---|---|---|---|---|
| Current Ratio (流动比率) | 0.2 | · | · | |
| Quick Ratio (速动比率) | 0.1 | · | · |
成长 营收、每股收益 (EPS) 和净利润增长:同比、3年复合年增长率 (CAGR)、5年复合年增长率 (CAGR)
| 指标 | 5年趋势 | ASBPW | 同行中位数 | 结论 |
|---|---|---|---|---|
| Net Income YoY (净利润同比增长) | 33.7% | · | · |
资本效率 资产周转率、库存周转率、应收账款周转率
基本面数据不足,尚无法计算此比率组。
价值 · 行业中位数 · 相对于中位数的评判
完整基本面 所有年度指标 — 损益表、资产负债表、现金流量表
损益表
| 指标 | 趋势 | 2025 |
|---|---|---|
| Revenue | $6.2K | |
| Cost of Revenue | $6.3K | |
| Gross Profit | $-116 | |
| R&D Expense | $923.9K | |
| SG&A Expense | $18M | |
| Operating Expenses | $19M | |
| Operating Income | $-19M | |
| Other Non-op | $-5M | |
| Pretax Income | $-24M | |
| Net Income | $-24M | |
| EPS (Diluted) | $-16.38 | |
| Shares (Basic) | 1,494,956 | |
| Shares (Diluted) | 1,494,956 | |
| EBITDA | $-19M |
资产负债表
| 指标 | 趋势 | 2025 |
|---|---|---|
| Cash & Equivalents | $1M | |
| Inventory | $253.2K | |
| Prepaid Expense | $55.1K | |
| Current Assets | $1M | |
| Total Assets | $1M | |
| Accounts Payable | $1M | |
| Accrued Liabilities | $1M | |
| Current Liabilities | $8M | |
| Total Liabilities | $8M | |
| Common Stock | $12 | |
| Paid-in Capital | $21M | |
| Retained Earnings | $-27M | |
| Stockholders' Equity | $-6M | |
| Liabilities + Equity | $1M | |
| Shares Outstanding | 117,780 |
现金流
| 指标 | 趋势 | 2025 |
|---|---|---|
| Stock-based Comp | $14M | |
| Operating Cash Flow | $-5M | |
| Financing Cash Flow | $6M | |
| Net Change in Cash | $1M |
盈利能力
| 指标 | 趋势 | 2025 |
|---|---|---|
| Gross Margin | -1.9% | |
| Operating Margin | -312017.0% | |
| Net Margin | -394725.1% | |
| Pretax Margin | -394725.1% | |
| EBITDA Margin | -312017.0% | |
| ROA | -3353.2% | |
| ROE | 306.1% |
流动性与偿付能力
| 指标 | 趋势 | 2025 |
|---|---|---|
| Current Ratio | 0.2 | |
| Quick Ratio | 0.1 |
效率
| 指标 | 趋势 | 2025 |
|---|---|---|
| Asset Turnover | 0.0 | |
| Inventory Turnover | 0.0 |
每股
| 指标 | 趋势 | 2025 |
|---|---|---|
| Book Value / Share | $-1.80 | |
| Revenue / Share | $0.00 | |
| Cash Flow / Share | $-3.29 | |
| Cash / Share | $0.28 | |
| EPS (TTM) | $-16.38 |
估值 (TTM)
| 指标 | 趋势 | 2025 |
|---|---|---|
| Revenue TTM | $6.2K | |
| Net Income TTM | $-24M |
损益表
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue | $63.1K | $28.4K | $4.3K | $1.9K | |
| Cost of Revenue | $50.8K | $22.6K | $5.3K | $1.1K | |
| Gross Profit | $-30.1K | $5.8K | $-1.0K | $884 | |
| R&D Expense | $233.5K | $296.7K | $100.0K | $207.9K | |
| SG&A Expense | $970.2K | $1M | $2M | $513.0K | |
| Operating Expenses | $3M | $2M | $2M | $1M | |
| Operating Income | $-3M | $-2M | $-2M | $-1M | |
| Interest Income | $56.7K | $5.0K | · | · | |
| Other Non-op | $1M | $-2M | $-3M | $-705.0K | |
| Pretax Income | $-1M | $-3M | · | · | |
| Net Income | $-1M | $-3M | $-5M | $-2M | |
| EPS (Basic) | $-1.22 | $-20.57 | · | $-0.04 | |
| EPS (Diluted) | $-1.22 | $-20.57 | $-15.95 | $-0.04 | |
| Shares (Basic) | 1,037,874 | 156,685 | -44,163,740 | 49,525,970 | |
| Shares (Diluted) | 1,037,874 | 156,685 | -44,163,740 | 49,525,970 | |
| EBITDA | $-3M | $-2M | · | $-1M |
资产负债表
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $12M | $6M | $1M | $2M | |
| Inventory | $288.4K | $370.0K | $253.2K | $35.4K | |
| Prepaid Expense | $1M | $890.1K | $55.1K | $419.4K | |
| Current Assets | $13M | $7M | $1M | $2M | |
| Total Assets | $14M | $7M | $1M | $2M | |
| Accounts Payable | $972.1K | $857.9K | $1M | $1M | |
| Accrued Liabilities | $714.1K | $441.6K | $1M | $266.9K | |
| Current Liabilities | $2M | $3M | $8M | $14M | |
| Total Liabilities | $2M | $3M | $8M | $14M | |
| Common Stock | $129 | $17 | $353 | $5.0K | |
| Paid-in Capital | $44M | $34M | $21M | $11M | |
| Retained Earnings | $-32M | $-30M | $-27M | $-23M | |
| Stockholders' Equity | $12M | $4M | $-6M | $-11M | |
| Liabilities + Equity | $14M | $7M | $1M | $2M | |
| Shares Outstanding | 1,295,234 | 167,470 | 3,533,408 | 49,525,970 |
现金流
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Stock-based Comp | $144.1K | $13.4K | $0 | $0 | |
| Operating Cash Flow | $-2M | $-3M | $-927.8K | $-1M | |
| Stock Issued | $9M | $9M | · | · | |
| Net Stock Activity | · | $9M | · | · | |
| Financing Cash Flow | $8M | $8M | $-16.5K | $3M | |
| Net Change in Cash | $6M | $5M | $-944.4K | $2M |
盈利能力
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Gross Margin | -47.7% | 20.3% | · | 45.5% | |
| Operating Margin | -4244.1% | -5806.0% | · | -59015.8% | |
| Net Margin | -2009.6% | -11367.0% | · | -95337.1% | |
| Pretax Margin | -2009.6% | -11367.0% | · | · | |
| EBITDA Margin | -4244.1% | -5806.0% | · | -59015.8% | |
| ROA | -17.5% | -71.0% | · | -40.8% | |
| ROE | -118.5% | 157.8% | · | 20.6% |
流动性与偿付能力
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Current Ratio | 8.0 | 2.3 | · | 0.2 | |
| Quick Ratio | 7.2 | 1.9 | · | 0.1 |
效率
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | · | 0.0 | |
| Inventory Turnover | 0.4 | 0.1 | · | 0.1 |
每股
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Book Value / Share | $9.08 | $23.10 | · | $-0.23 | |
| Revenue / Share | $0.06 | $0.18 | · | $0.00 | |
| Cash Flow / Share | · | $-19.39 | · | · | |
| Cash / Share | $9.39 | $34.97 | · | $0.04 | |
| EPS (TTM) | $-70.02 | · | · | · |
估值 (TTM)
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Net Income TTM | $-8M | $-23M | · | $-21M | |
| Market Cap | $25.9K | $3.3K | · | · | |
| P/E | -0.0 | · | · | · | |
| P/B | 0.0 | 0.0 | · | · | |
| P / Tangible Book | 0.0 | 0.0 | · | · | |
| P / Cash Flow | · | -0.0 | · | · | |
| Earnings Yield | -350100.0% | · | · | · |
最近期在左侧 · 空值显示为 ·
财务报表 损益表、资产负债表、现金流量表 — 年度,近5年
| 指标 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| 收入 | $6.2K | · | · | · | · |
| 毛利率 % | -1.9% | · | · | · | · |
| 营业利润率 % | -312017.0% | · | · | · | · |
| 净收入 | $-24M | $-1M | $4M | $3M | $-25.5K |
| 稀释后每股收益 (EPS) | $-16.38 | $-1.90 | · | · | · |
| 指标 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| 流动比率 | 0.2 | 0.0 | 0.2 | 3.6 | · |
| 速动比率 | 0.1 | · | · | 1.6 | · |
基本面数据不足,尚无法生成此报表。
机构持有人 (13F) 34 家申报者 · $170K 总计 · 截至 2026年6月30日
在其季度SEC表格13F中报告持有此股票的机构。仅限多头头寸;单个申报人可能因单独的期权腿而出现两次。 大的抵消性看跌/看涨腿通常反映做市或对冲库存,而非方向性判断。
| 新仓位 | 已退出持仓 | 增加 | 减少 | 净股数变动 |
|---|---|---|---|---|
| 1 (0 与上一季度对比) | 3 (+3 与上一季度对比) | 1 (0 与上一季度对比) | 3 (-2 与上一季度对比) | -283K |
与Q1 2026对比。 SEC 13F表格的提交截止日期是季度末后45天,外加少量延迟提交的缓冲期——在此窗口期内的季度将被跳过,优先显示最近一个已完整报告的季度对。
激进投资者及 5%+ 股东 1 持仓
提交了 SEC Schedule 13D 的投资者 — 持有超过 5% 的受益所有权,意图影响发行人(激进股东持股、董事会活动、并购)。每一行显示该申报人持仓的最新已知状态。
| 申报人 | 已申报 | 持股 | 状态 | 目的 | 申报 |
|---|---|---|---|---|---|
| SRIRAMA Associates, LLC, Surendra Ajjarapu | 2023年9月5日 | · | 初始申报 | 被动投资 | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
我的指标 您的个人关注列表 — 来自完整基本面的选定行
选择对您重要的指标 — 点击上方完整基本面中任意行的 + 号。
您的选择已保存,并会跟随您浏览所有股票。